1004316-92-0 Usage
General Description
(S)-2-(3-((2-isopropylthiazol-4-yl)Methyl)-3-Methylureido)-4-Morpholinobutanoic acid is a chemical compound with a highly complex and specific structure. The presence of different functional groups like thiazole, ureido, and morpholine in its structure indicates that it may have a variety of chemical and biological properties. Thiazoles are notably present in a number of pharmaceutical drugs and are known for their bioactive properties. Ureido group is a common feature in many biological compounds, particularly in antibiotics. Morpholine is a versatile building block in organic synthesis and is prevalent in a wide array of medicinal compounds. It's also noteworthy to mention that the (S)-2- prefix indicates that the compound is chiral, meaning it has a specific 3D spatial arrangement that cannot be superimposed onto its mirror image. However, without extensive research, it is impossible to accurately predict the exact properties and potential applications of such a compound.
Check Digit Verification of cas no
The CAS Registry Mumber 1004316-92-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,4,3,1 and 6 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1004316-92:
(9*1)+(8*0)+(7*0)+(6*4)+(5*3)+(4*1)+(3*6)+(2*9)+(1*2)=90
90 % 10 = 0
So 1004316-92-0 is a valid CAS Registry Number.
1004316-92-0Relevant articles and documents
INHIBITORS OF CYTOCHROME P450
-
, (2015/11/10)
The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
-
Page/Page column 220-221, (2008/06/13)
The present application provides for a compound of Formula I, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
